Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) received a ‘Hold’ rating from Wells Fargo, which set the company’s stock price ...

Regeneron Inc. seeks to disqualify Kirkland & Ellis from representing its opponent Novartis AG in a major antitrust and ...

Findings that U.S. companies can sue foreign rivals despite limited business operations in the country could dissuade drug ...

Market is one of the leading causes of irreversible vision loss in individuals aged 50 and above. With the global aging population increasing rapidly, the burden of AMD is escalating, pushing the ...

Axpaxli is Ocular's main value driver, targeting a large wet AMD market with a differentiated, sustained-release TKI ...

The first successes of the turnaround are visible,' said Markus Manns, a portfolio manager at Union Investment in Frankfurt.

They all had severe disease and a high treatment burden with an average of 10 injections with Eylea (aflibercept), a widely-used VEGF inhibitor sold by Bayer and Regeneron, in the last 12 months.

Novartis is launching a head-to-head trial of its experimental brolucizumab therapy for age-related macular degeneration (AMD) against Bayer/Regeneron’s Eylea, the market leader. The TALON trial ...

DRI Healthcare Trust’s strong balance sheet and effective cash flow management are overshadowed by profitability challenges due to revenue decline and net losses. Technical anal ...